224 results on '"Jongs, Niels"'
Search Results
2. Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex
3. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
4. Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial
5. Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria
6. Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
7. Clinical trial designs to assess treatment effects on glomerular filtration rate decline
8. Digital behavioural signatures reveal trans-diagnostic clusters of Schizophrenia and Alzheimer's disease patients
9. Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials
10. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression
11. Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review
12. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease
13. Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials
14. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
15. WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
16. WCN24-1229 EFFECTS OF TREATMENT AND CLINICAL EVENTS ON QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PRESPECIFIED ANALYSIS OF THE DAPA-CKD TRIAL
17. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
18. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
19. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
20. The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
21. Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients
22. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
23. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
24. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
25. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
26. Response to Comment on Curovic et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Diabetes Care 2023;46:593–601
27. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
28. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
29. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
30. Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex
31. Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE‐3 study
32. Development and Validation of a New Hierarchical Composite Endpoint for Clinical Trials of Kidney Disease Progression
33. Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial
34. Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease
35. Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE‐3 study.
36. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty.
37. The authors reply
38. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials
39. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty
40. Overall and inter‐individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes
41. A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data
42. Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial
43. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
44. Effects of albuminuria‐lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials
45. Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America
46. Effects of Dapagliflozin on Kidney Function, Cardiovascular Events, and All-Cause Mortality According to Cause of Kidney Disease in the DAPA-CKD Trial: FR-OR58
47. Albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes: a randomized cross‐over clinical study
48. Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
49. Efficacy of dapagliflozin by baseline diabetes medications: A prespecified analysis from the DAPA-CKD study
50. Optimization of albuminuria lowering treatment in diabetes by cross-over rotation to four different drug classes – a randomized cross-over trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.